Results 61 to 70 of about 48,364 (325)
BMC Pharmacology and Toxicology, 2019 Background Apixaban effectively lowers the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. Systemic exposure to a given apixaban dose depends on multiple clearance pathways.
Andrea Huppertz +9 more
doaj +1 more source
Extended thromboprophylaxis with betrixaban in acutely ill medical patients [PDF]
, 2016 BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.
. Lodigiani, M +18 more
core +1 more source
Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease
Annals of Internal Medicine, 2022 BACKGROUND Although apixaban and rivaroxaban are commonly used in patients with atrial fibrillation (AF) and valvular heart disease (VHD), there is limited evidence comparing the 2 drugs in these patients.
G. Dawwas +4 more
semanticscholar +1 more source
TH Open, 2018 Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim +7 more
doaj +1 more source
Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points
CJC Open, 2020 Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD +1 more
doaj +1 more source
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]
, 2018 © 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J +2 more
core +3 more sources
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Thrombosis and Haemostasis, 2020 Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.
H. Billett +11 more
semanticscholar +1 more source
American Society of Nephrology. Clinical Journal, 2022 Visual Abstract Background and objectives The association of apixaban compared with warfarin for the treatment of venous thromboembolism in patients receiving maintenance dialysis is not well studied.
J. Wetmore +5 more
semanticscholar +1 more source
Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]
, 2015 Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core +3 more sources
Blood Advances, 2022 Key Points • D-dimer testing may help to decide on extended treatment after VTE; this was never assessed since DOACs are available.• Exceedingly more outcomes in patients off anticoagulation for negative D-dimer than in those receiving apixaban for ...
G. Palareti +24 more
semanticscholar +1 more source